

Executive Management

Dennis Wahr, M.D. **President and Chief Executive Officer**

Dennis Wahr, M.D., joined Nuvaira in September 2012 with a unique background in serial medical device development, clinical evaluation and commercialization experience. Prior to joining Nuvaira, Dr. Wahr co-founded Lutonix in 2007 and served as its president and CEO until CR Bard acquired the company in December 2011. Preceding its acquisition, Lutonix developed a unique drug coated balloon angioplasty technology for the treatment and prevention of vascular stenosis caused by atherosclerosis. Prior to Lutonix, Dr. Wahr co-founded Velocimed in 2001, and served as its president and CEO until its acquisition by St. Jude Medical in 2005.

As a company CEO, Dr. Wahr has a wide range of experience with both the European regulatory authorities and the U.S. Food and Drug Administration (FDA). His companies have sponsored nine clinical trials involving more than 1,500 patients leading to approvals for four innovative medical products. Dr. Wahr has served on the board of directors of several medical device companies including Accumetrics, IDev, Velocimed, and Lutonix, and he currently serves as chairman of the board for Intact Vascular. Additionally, Dr. Wahr spent two years as a managing director with RiverVest Ventures focusing on capital investments in emerging medical technology companies.

Dr. Wahr received a Bachelor of Arts from Albion College and his Medical degree from Wayne State University School of Medicine. He did a fellowship in interventional cardiology at the University of California, San Francisco, and he is currently board certified in interventional cardiology. He spent more than 14 years in clinical practice and served as the chief of cardiology at the Michigan Heart and Vascular Institute in Ann Arbor, Mich., prior to launching his entrepreneurial career.

Martin Mayse, M.D. **Founder and Chief Technology Officer**

Martin Mayse, M.D., co-founded Nuvaira in 2008 and invented the core technology, overseeing the pre-clinical and clinical work. In his current role as chief technology officer, Dr. Mayse continues to refine the technology to develop a broad base for commercially viable products. Prior to founding Nuvaira, Dr. Mayse was the director of interventional pulmonary medicine and an associate professor of medicine and surgery at Washington University School of Medicine. In St. Louis for nearly six years, Dr. Mayse established the interventional pulmonology program for Washington University/Barnes Jewish Hospital. Concurrent with his university duties, Dr. Mayse also served as a part-time consultant to Calypso Medical (acquired by Varian Medical Systems) as the company developed a device to guide radiation therapy for lung cancer patients. Earlier in his career, Dr. Mayse was an instructor of medicine at Tulane University. Dr. Mayse has participated in numerous clinical research projects in the field of interventional pulmonology. He has published research in many peer-reviewed journals and is the author of book chapters and abstracts.

Dr. Mayse holds a Bachelor of Science degree in Biomedical Engineering from Wright State University and a Medical degree from Yale University School of Medicine. Dr. Mayse did a fellowship in pulmonary and critical care medicine at Yale University and is board certified in internal medicine and pulmonology.

Shane Gleason
Chief Commercial Officer

Shane Gleason joined Nuvaira in May 2017, bringing with him 18 years of healthcare sales and operations experience. Most recently, Mr. Gleason served as vice president of sales for North America at Cordis, a Cardinal Health company, where he led the North American sales integration efforts of two sales forces and led the combined 200-plus-member team. Before joining Cordis, Mr. Gleason was vice president of U.S. Sales at TriVascular, where he built and led the U.S. sales organization to support the launch and commercialization of its abdominal stent graft system. Prior to joining TriVascular, Mr. Gleason held a variety of leadership roles at Abbott, including leading global and strategic marketing for Abbott's endovascular franchise and professional education. Prior to Abbott, he held sales positions with Smiths Medical-Level 1 and Medline Industries.

Mr. Gleason holds a Bachelor of Science degree in Engineering Science and Mechanics with a concentration in Biomechanical Engineering from Virginia Polytechnic Institute and State University, and a Master's degree in Business Administration from the Robert H. Smith School of Business at the University of Maryland.

Kari Kubesh
Chief Financial Officer

Kari Kubesh joined Nuvaira in December 2012 with more than 15 years of finance experience, including more than 10 years with early stage life science companies. Ms. Kubesh recently served as vice president of finance and administration at Lutonix, Inc., a vascular device start up acquired by CR Bard, Inc. in 2011. Prior to this, she served as controller at Velocimed, LLC, a medical device company acquired by St. Jude Medical in 2005. Before joining Velocimed, Ms. Kubesh was employed by the public accounting firm of Deloitte & Touche LLP, where she focused on emerging markets and the life science industry.

Ms. Kubesh holds a Bachelor of Arts degree in Accounting from the University of St. Thomas and is a member of the MNCPA and AICPA.

Steve Mertens
Senior Vice President of Operations

Steve Mertens joined Nuvaira in November 2012, bringing with him more than 20 years of medical device operational experience. His current responsibilities include management of Research and Development, Quality and Manufacturing. Prior to joining Nuvaira, Mr. Mertens was a senior vice president of research and development for Boston Scientific. For 16 years, Mr. Mertens guided a wide range of technologies through product development for the cardiology, electrophysiology and peripheral vascular markets. Mr. Mertens began his medical device career working in engineering, quality and manufacturing roles at Scimed Life Sciences. Earlier, he worked on computer components in the electronics industry. He is a co-inventor on 18 issued U.S. patents. Mr. Mertens has been chairman of LifeScience Alley, a Minnesota-based trade association where he worked to improve the Life Science industry. He was a board member of University Enterprise Laboratories, which is a collaborative research center that supports early stage bioscience companies in Minnesota.

Mr. Mertens holds a Bachelor of Science degree in Chemical Engineering from the University of Minnesota and a Master's degree in Business Administration from the University of St. Thomas.

Mahtab Fatemi
Vice President of Regulatory Affairs and Quality

Mahtab Fatemi joined Nuvaira in late 2012 with more than 14 years of experience in executing regulatory strategies for pharmaceuticals and medical devices. In her current role, she develops and oversees corporate efforts to ensure that developed products meet the requirements of the U.S. Food and Drug Administration (FDA) and other international regulatory authorities. Prior to joining Nuvaira, Ms. Fatemi ran an independent regulatory consulting business for four years where clients included Broncus Medical, a developer of diagnostic and therapeutic technologies to treat patients with lung disease. Ms. Fatemi spent two years at MAP Pharmaceuticals as director of regulatory affairs overseeing both U.S. and global submissions. She began her career as a regulatory affairs specialist at BD Biosciences where she worked for seven years.

Ms. Fatemi holds a Bachelor of Science in Biology from the University of California, Irvine, and a Master of Science degree in Physiology from Georgetown University. She also has a Juris Doctor from Santa Clara University and is currently a member of the California Bar.

Jim Pavliska
Vice President of Clinical Affairs

Jim Pavliska joined Nuvaira in January 2013 and brings more than 15 years of clinical research experience to the position. His broad research expertise and passion for human research bring valuable insight to the clinical program at Nuvaira. Prior to joining Nuvaira, Mr. Pavliska was the clinical director at Lutonix, Inc. for four years (acquired by CR Bard, Inc. in 2011). His responsibilities included overseeing pre-clinical and clinical research, including study design, FDA & IRB/EC approvals, and study execution for a drug-coated balloon catheter. Mr. Pavliska began his research experience at Brigham and Women's Hospital in Boston, where he coordinated interventional research. He joined start-up, PercuSurge (later acquired by Medtronic) in 1998 to manage field research activities. He then went on to spend seven years at Velocimed/St. Jude, building the clinical program as clinical research director, and later as director of interventional research following the acquisition.

Mr. Pavliska holds a Bachelor of Science degree in Biomedical Science from Texas A&M University.

###